Carbamazepine (Epilepsy)

Polydactyly

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S382
R16397		 Tomson (Carbamazepine), 2018 Polydactyly at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 6.43 [0.31;134.02] C 2/1,957   0/2,514 2 1,957
ref
S5483
R15650		 Bànhidy (Carbamazepine), 2011 Poly/syndactyly throughout pregnancy case control unexposed, sick Adjustment: No Matched 0.30 [0.01;8.33] C 0/10   2/12 2 10
ref
S5529
R16227		 Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 Polydactyly throughout pregnancy prospective cohort unexposed, sick Adjustment: No 2.19 [0.09;54.89] C 1/72   0/52 1 72
ref
S6685
R18581		 D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 Extra digits throughout pregnancy prospective cohort unexposed, disease free excluded Adjustment: No Matched 123.00 [3.40;4444.20] C
excluded (control group) 		1/3   0/62 1 3
ref
S6689
R18698		 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 Extra digits throughout pregnancy prospective cohort unexposed, sick Adjustment: No 15.00 [0.39;576.73] C 1/3   0/8 1 3
ref
Total 4 studies 2.73 [0.53;14.09] 6 2,042
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Tomson (Carbamazepine), 2018Tomson, 2018 1 6.43[0.31; 134.02]21,95729%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Bànhidy (Carbamazepine), 2011Bànhidy, 2011 2 0.30[0.01; 8.33]21024%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006Viinikainen, 2006 3 2.19[0.09; 54.89]17226%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate D'Souza (Carbamazepine) (Controls unexposed, sick), 1991D'Souza, 1991 4 15.00[0.39; 576.73]1320%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 0% 2.73[0.53; 14.09]62,0420.250.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine; 2: Carbamazepine; 3: Carbamazepine) (Controls unexposed, sick) ; 4: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 5.57[0.84; 36.88]42,0320%NATomson (Carbamazepine), 2018 Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 3 case control studiescase control studies 0.30[0.01; 8.33]210 -NABànhidy (Carbamazepine), 2011 1 Type of controls unexposed, sickunexposed, sick 1.95[0.23; 16.74]48517%NABànhidy (Carbamazepine), 2011 Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 3 exposed to other treatment, sickexposed to other treatment, sick 6.43[0.31; 134.02]21,957 -NATomson (Carbamazepine), 2018 1 Tags Adjustment   - No  - No 2.73[0.53; 14.09]62,0420%NATomson (Carbamazepine), 2018 Bànhidy (Carbamazepine), 2011 Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 4 MatchedMatched 0.30[0.01; 8.33]210 -NABànhidy (Carbamazepine), 2011 1 All studiesAll studies 2.73[0.53; 14.09]62,0420%NATomson (Carbamazepine), 2018 Bànhidy (Carbamazepine), 2011 Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 40.150.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.45.42.2340.000Tomson (Carbamazepine), 2018Bànhidy (Carbamazepine), 2011Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006D'Souza (Carbamazepine) (Controls unexposed, sick), 1991

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 6685

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale123.00[3.40; 4444.20]13 -NAD'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 1 unexposed, sick controlsunexposed, sick controls 1.95[0.23; 16.74]48517%NABànhidy (Carbamazepine), 2011 Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 6.43[0.31; 134.02]21,957 -NATomson (Carbamazepine), 2018 10.510.01.0